Armata Pharmaceuticals Launches Advanced cGMP Phage Plant
Los Angeles, California, November 10, 2025 — Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company pioneering bacteriophage (phage) therapeutics targeting...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Los Angeles, California, November 10, 2025 — Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company pioneering bacteriophage (phage) therapeutics targeting...
NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...
San Rafael, California — October 30, 2025 — BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration...
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
Nanjing, China – October 22, 2025 GemPharmatech Co., Ltd., a global leader in genetically engineered mouse models and preclinical...
THOUSAND OAKS, Calif., October 17, 2025 — In a landmark regulatory decision, the U.S. Food and Drug Administration (FDA)...
Budapest / London, September 29, 2025 Gedeon Richter and Hikma announced that the U.S. Food and Drug Administration (FDA)...
Boston, September 29, 2025 Vor Bio has announced that late-breaking Phase 3 clinical data of telitacicept in primary Sjögren’s...
September 22, 2025 – Brussels, Belgium – AstraZeneca and Amgen announced that the European Medicines Agency’s (EMA) Committee for...
HOUSTON, Sept. 16, 2025 – Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company specializing in regulatory T cell...
